Sonoma Pharmaceuticals Investor Presentation — August 2018

Document content

NASDAQ: SNOASONOMA PHARMACEUTICALSRESULTS FOR THE QUARTER ENDING 30 JUNE 2018August 8, 2018

2Welcome / IntroductionJune Quarter 2018 HighlightsFinancial Review Q+AJim SchutzBob MillerNASDAQ: SNOAPage

Forward-Looking StatementExcept for historical information herein, matters set forth in this presentation are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”).These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this presentation are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, andother risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.3NASDAQ: SNOAPage

Results from the Quarter Ending 30 June 2018

4Total Revenue = $4.4M Up 14% versus same period last yearUp 20% versus the quarter ending 31 Mar 2018U.S. dermatology revenue = $1.2MUp 1% versus same period last yearUp 55% versus the quarter ending 31 Mar 2018International revenue = $2.1MUp 22% versus same period last yearUp 11% versus the quarter ending 31 Mar 2018Cash as of 30 June 2018 = $7.7MNASDAQ: SNOAPage

Upcoming MilestonesFall 2018 Brazil –commercialization / product launches of acne and scar management product linesSecond Half of 2018US –product launch for prescription antimicrobial facial rinse as part of an acne regimenSecond Half of 2018US –product launch for Ceramaxlotion indicated for atopic dermatitisLate 2018US –home-delivery / direct-to-patient pharmacy program capture 60% of prescriptions filled for SNOA’s products

5June 2018 QTRvs June 2017 QTR& March 2018 QTR